Skip to content
DataLookout
Menu

NCT04147013

Effect of Celecoxib on Postoperative Analgesia and Disease Severity in AERD Patients with CRS

StatusUnknown
PhasePhase 4
Primary completion (estimated)
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 8 versions: 8 with changes below. See every version on ClinicalTrials.gov ↗

  1. Minor Changed Registry marked status Unknown (sponsor has not verified the record since Oct 2024); last known: Active, Not Recruiting
  2. Notable Primary completion date: Feb 2025 to Feb 2026
    • Trial status: Recruiting to Active, Not Recruiting
    • Study completion date: Apr 2025 to Jul 2026
    • Site details revised at 2 of 2 sites
    v8
  3. Minor Study sites: 1 to 2v7
  4. Notable Primary completion date: Jan 2023 to Feb 2025
    • Study completion date: Apr 2023 to Apr 2025
    • Collaborators revised (2)
    v6
  5. Notable Primary completion date: Jan 2022 to Jan 2023
    • Study completion date: Apr 2022 to Apr 2023
    v5
Show 3 earlier versionsHide 3 earlier versions
  1. Notable Eligibility criteria expanded, about 21 wordsv4
  2. Notable Primary completion date: Dec 2020 to Jan 2022
    • Study completion date: Jan 2021 to Apr 2022
    v3
  3. Notable Trial status: Not Yet Recruiting to Recruiting
    • Start date changed from estimate of Jan 2020 to Feb 18, 2020
    • Site details revised
    v2
  1. Study First Submitted
  • Notable: the plan changed
  • Minor: routine updates

Endpoints

Primary

Post FESS changes in the Lund-Kennedy Endoscopic Score (LKES)
Timeframe: 1 week and 4 weeks post-operatively.
Post FESS changes in the Peri-Operative Sinus Endoscopy (POSE) score
Timeframe: 1 week and 4 weeks post-operatively.
Post FESS changes in the validated Sino-Nasal Outcome Test 22 (SNOT-22) questionnaire
Timeframe: 1 week and 4 weeks post-operatively.

Secondary (1)

Post FESS changes in the pain level assessed via the 10-point visual analogue scale

Arms and interventions

Celecoxib GroupExperimental

Patients will receive the interventional drug for 7 days post endoscopic sinus surgery. These patients will also receive a prescription for tramadol (50 mg PO Q6H PRN x 10 tablets), to be used as needed for breakthrough pain. Patients will also be permitted to take acetaminophen for breakthrough pain as needed and will be encouraged to use acetaminophen prior to narcotic usage. Finally, they will be prescribed a nasal saline rinse, which is to be started on postoperative day one.

Control GroupPlacebo comparator

Patients will receive the placebo for 7 days post endoscopic sinus surgery. These patients will also receive a prescription for tramadol (50 mg PO Q6H PRN x 10 tablets), to be used as needed for breakthrough pain. Patients will also be permitted to take acetaminophen for breakthrough pain as needed and will be encouraged to use acetaminophen prior to narcotic usage. Finally, they will be prescribed a nasal saline rinse, which is to be started on postoperative day one.

Drugs: Celecoxib, Placebo

Sites

2 sites in 2 countries

Canada 1, Saudi Arabia 1